Pipeline-in-a-drug, page-56

Thanks very much Hottod! I am completely uneducated when it comes to contracts and legal terminology but from reading your post the first thing that comes to mind is 'who constitutes the JSC and would likely control its decision making'? From clause 6.2 it says Acadia needs to seek permission from the JSC to develop Trof in indications outside Retts and Fragile X. Would not a good reason to deny this be that Neuren has already committed significant resources to achieving FDA approval in this New indication? Only if Acadia controls the JSC would you imagine them receiving clause 6.2 approval and thereby halt Neuren's North American development as discussed in clause 11?